Today, Research to Prevent Blindness (RPB) and more than 30 other organizations are convening in Washington DC for the Vision Research Funding Partnership event, which was organized around the theme of “The Research Pipeline – From Premise to Patient.”
Researchers supported by the National Eye Institute are developing artificial intelligence/machine learning (AI/ML)-based systems that not only screen for AMD but also predict which patients will likely progress to late within two years. The systems also evaluate separately one’s risk for developing late wet (neovascular) AMD from one’s risk for late dry (geographic atrophy) AMD.
Researchers at Tel Aviv University identified a new genetic risk factor for the complex eye disease AMD (Age-related Macular Degeneration), a leading cause for loss of eyesight at an advanced age.
The American Macular Degeneration Foundation will be hosting multiple, awareness-spreading activities throughout February, which is AMD Awareness Month, including new films on living well with AMD.
Rockville, Md.—The Association for Research in Vision and Ophthalmology (ARVO) Foundation congratulates Miguel Flores-Bellver, PhD, recipient of the 2023 Bert M. Glaser, MD Award for Innovative Research in Retina. The award recognizes an early-career investigator who has made a novel discovery that impacted the understanding and/or treatment of a retinal disease or condition.
Researchers discover new clues for causes of adult-onset macular degeneration.
Recent evidence has emerged to suggest that age-related macular degeneration (AMD) is a clinical risk factor for increased risk for infection and mortality.
The foundation is investing $1.1 million in studies that hold the potential to set new standards in the prevention and treatment of age-related macular degeneration
Research to Prevent Blindness announces a new round of awardees who are generating critical knowledge around a host of sight-threatening conditions. With this latest round of funding, RPB has provided more than $400 million in research funding.
Patients with a specific form of age-related macular degeneration (AMD), a leading cause of blindness in the United States, are also highly likely to have either underlying heart damage from heart failure and heart attacks, or advanced heart valve disease, or carotid artery disease associated with certain types of strokes, according to a new study from New York Eye and Ear Infirmary of Mount Sinai.
National Eye Institute researchers mapped the organization of human retinal cell chromatin, the fibers that package 3 billion nucleotide-long DNA molecules into compact structures that fit into chromosomes within each cell’s nucleus. The resulting comprehensive gene regulatory network provides insights into regulation of gene expression in general, and in retinal function, in both rare and common eye diseases. The study published in Nature Communications.
Patients with a specific form of age-related macular degeneration (AMD), a leading cause of blindness in the United States, are at significant risk for cardiovascular disease and stroke, according to new research from New York Eye and Ear Infirmary of Mount Sinai.
The American Academy of Ophthalmology is highlighting what the next decade may hold for the 11 million Americans suffering from AMD.
A new artificial intelligence (AI) algorithm developed by researchers at New York Eye and Ear Infirmary of Mount Sinai (NYEE) can rapidly and accurately detect age-related macular degeneration (AMD), a leading cause of vision loss in the United States.
National Eye Institute (NEI) researchers profiling epigenomic changes in light-sensing mouse photoreceptors have a clearer picture of how age-related eye diseases may be linked to age-related changes in the regulation of gene expression. The findings, published online April 21 in Cell Reports, suggest that the epigenome could be targeted as a therapeutic strategy to prevent leading causes of vision loss, such as age-related macular degeneration (AMD).
Answers from trusted sources regarding macular degeneration care during the COVID-19 outbreak.
A protein that normally deposits mineralized calcium in tooth enamel may also be responsible for calcium deposits in the back of the eye in people with dry age-related macular degeneration (AMD), according to a study from researchers at the National Eye Institute (NEI).
During February, the American Academy of Ophthalmology is urging people to protect themselves from vision loss from AMD by getting a baseline eye exam by age 40.
It would be the first treatment for "dry" age-related macular degeneration and could significantly improve treatment for wet AMD.
Christine Curcio, PhD, has been selected as the 2019 RPB David F. Weeks Award for Outstanding AMD Research (Weeks Award). The Weeks Award, funded through the generosity of Research to Prevent Blindness (RPB), an anonymous donor, and the Association of University Professors of Ophthalmology (AUPO), annually recognizes and celebrates an excellent researcher focused on age-related macular degeneration (AMD).
Showing results
1–20 of 20
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
